A Phase 1/2, Open-Label, Dose-Escalation, Single Center, Clinical Study of MTP-131 (Ocuvia) Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration.

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Single Center, Clinical Study of MTP-131 (Ocuvia) Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Age-related macular degeneration; Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ReVIEW
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 23 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jun 2015 Results were presented in New York City at Stealth second Mitochondrial Science and Medicine Series symposium focused on mitochondria role in ophthalmology according to Stealth BioTherapeutics media release.
    • 25 Jun 2015 Results published in the Stealth BioTherapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top